Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford

This study aims to assess the feasibility of performing neuropsychological testing to measure the cognitive performance of individuals following Axicabtagene ciloleucel CAR-T therapy at Stanford.

Stanford is currently not accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • behavioral: Neuropsychological testing

Eligibility


Inclusion Criteria:

   - >/= 18 years-old

   - Treated with Axicabtagene ciloleucel CAR-T therapy at Stanford Or

   - Treated with standard commercial Axicabtagene ciloleucel CAR-T therapy elsewhere and
   followed primarily by SHC Blood and Bone Marrow transplant providers

   - >/= 6 months from the date of CAR-T infusion

   - Fluent in English

   - Able to attend and participate in in-person testing (Arm I)

   - Able to participate in remote video testing with adequate workspace, computer and
   internet capabilities for a reliable telehealth video connection (Arm II)

Exclusion Criteria:

   - Concurrent enrollment in a CAR-T therapeutics research study

   - Unable to be present for the scheduled testing

   - Unable to participate in testing due to severe cognitive or physical limitation

   - Actively receiving chemotherapy

   - Progressive cancer

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Brian J Scott, MD
bjscott@stanford.edu
Not Recruiting

Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation,  mobile application development, and pharmaceutical trials.  

Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.